Document:

Securities Purchase Agreement

 Exhibit 10.52 
  
 SECURITIES PURCHASE AGREEMENT 
  

HealtheTech, Inc. 
 523 Park Point Drive, 3rd Floor 
 Golden, Colorado 80401 
  
 The undersigned (the “Investor”), hereby confirms its agreement with you as follows: 
  
 1. This Securities Purchase Agreement (the “Agreement”) is made as of the date set forth below between
HEALTHETECH, INC., a Delaware corporation (the “Company”), and the Investor. 
  
 2. The Company has authorized the sale and issuance of (a) such number of shares (the “Shares”) of common stock of the Company, $0.001 par value per
share (the “Common Stock”) as shall be equal to (i) $14,000,000 divided by (ii) the Purchase Price (as such term is defined in the Terms and Conditions for Purchase of Securities attached hereto as Annex I), and (b) warrants
(collectively, the “Warrants”) to purchase an aggregate of approximately such number of shares of Common Stock (the “Warrant Shares”) as shall be equal to (i) 70% of the Investors’ aggregate purchase prices for the Shares
divided by (ii) the Purchase Price, to certain investors in a private placement (the “Offering”). The Shares and the Warrant Shares shall hereinafter be referred to as the “Securities.” The Warrants shall be in substantially the
form attached hereto as Annex II. The exercise price per Warrant Share shall be equal to the Purchase Price. 
  
 3. The Company and the Investor agree that the Investor will purchase from the Company, and the Company will issue and sell to the Investor (a) such number of
Shares as shall be equal to the aggregate purchase price of $                         (the “Aggregate Purchase
Price”) divided by (ii) the Purchase Price (as such term is defined in the Terms and Conditions for Purchase of Securities attached hereto as Annex I), and (b) a warrant (the “Warrant”) to purchase such number Warrant
Shares as shall be equal to (i) 70% of the Investor’s Aggregate Purchase Price divided by (ii) the Purchase Price, each pursuant to the Terms and Conditions for Purchase of Securities attached hereto as Annex I and incorporated
herein by this reference as if fully set forth herein. Unless otherwise requested by the Investor, certificates representing the Shares and the Warrant purchased by the Investor will be registered in the Investor’s name and address as set forth
below. 
  
 4. In the event of changes in the outstanding Common Stock of
the Company between the Definitive Agreement Date (as such term is defined in the Terms and Conditions for Purchase of Securities attached hereto as Annex I) and the Closing Date (as such term is defined in the Terms and Conditions for
Purchase of Securities attached hereto as Annex I) by reason of stock dividends, splits, recapitalizations, or the like, the Purchase Price shall be correspondingly adjusted to the Purchase Price that would have been determined in
accordance with the Terms and Conditions for Purchase of Securities attached hereto as Annex I had such stock dividend, split or recapitalization occurred prior to the execution of this Agreement. 
  
 5. The Investor represents that, except as set forth below, (a) it has had no
position, office or other material relationship within the past three years with the Company or its affiliates, (b) neither it, nor any group of which it is a member or to which it is related, beneficially owns (including the right to acquire or
vote) any securities of the Company and (c) it has no direct or indirect affiliation or association with any NASD member. Exceptions: 
  

	
	                                      
                                        
                                        
                                        
                                        
                                        
                    
	
	                                      
                                        
                                        
                                        
                                        
                                        
                    

 (If no exceptions, write “none.” If left blank, response will be deemed to be
“none.”) 
  

 1. 

 Please confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below
for that purpose. 
  

	 Dated as of: September     , 2003

	
	_________________________________________
	“INVESTOR”
	
	 By:_______________________________________

	
	 Print Name:_________________________________

	
	 Title:______________________________________

	
	 Address:___________________________________

	
	__________________________________________

  
 AGREED AND ACCEPTED: 
 HEALTHETECH, INC. 
  

	
	 By:_______________________________________

	
	 Print Name:_________________________________

	
	 Title:______________________________________

  

 2. 

 ANNEX I 
  

TERMS AND CONDITIONS FOR PURCHASE OF SECURITIES 
  
 1. Authorization and Sale of the Shares and the Warrants. Subject to the terms and conditions of this Agreement, the Company has authorized
the sale and issuance of the Shares, the Warrants and the Warrant Shares. 
  
 2. Agreement to Sell and Purchase the Shares and the Warrant.  
  
 2.1 At the Closing (as defined in Section 3), the Company will sell to the Investor, and the Investor will purchase from the Company, upon the
terms and conditions hereinafter set forth, (a) the number of Shares as determined in accordance with the provisions set forth on the signature page to which these Terms and Conditions for Purchase of Securities are attached as Annex I
(the “Signature Page”) and (b) a Warrant exercisable for that number of Warrant Shares determined in accordance with the provisions set forth on the Signature Page, for the Aggregate Purchase Price as set forth on such Signature Page.

  
 2.2 The Company proposes to enter into this same form
of Securities Purchase Agreement with certain other investors (the “Other Investors”) and expects to complete sales of Shares and Warrants to them. (The Investor and the Other Investors are hereinafter sometimes collectively referred to as
the “Investors,” and this Agreement and the Securities Purchase Agreements executed by the Other Investors are hereinafter sometimes collectively referred to as the “Agreements.”) The earliest date that Investors participating in
the Offering execute this form of Securities Purchase Agreement shall be referred to herein as the “Definitive Agreement Date”. The average of the closing sale prices of the Common Stock on the Nasdaq National Market (“Nasdaq”)
for the thirty (30) trading days immediately preceding and ending on the last trading day prior to the Definitive Agreement Date shall be referred to herein as the “Reference Price”. The Company will accept executed Agreements from
Investors for the purchase of Shares and Warrants commencing upon the Definitive Agreement Date and concluding upon the date on which the Company has (i) executed Agreements with Investors for the purchase of Shares and Warrants and (ii) notified
the Investors that it is no longer accepting Agreements from Investors for the purchase of Shares and Warrants. The purchase price per Share (the “Purchase Price”) shall be determined as follows: (A) for all Investors who execute
Agreements on or before the end of the second business day after the Definitive Agreement Date (the “Initial Investors”), the Purchase Price shall be equal to the Reference Price; and (B) for all Investors other than Initial Investors, the
Purchase Price shall be equal to average of the closing sale prices of the Common Stock on Nasdaq for the thirty (30) trading days immediately preceding and ending on the last trading day prior to the date this Agreement is executed by such Investor
(the “Subsequent Investor Price”); provided, however, that if the Subsequent Investor Price is less than the Reference Price, then the Purchase Price for such Investor shall be equal to the Reference Price. 
  
 3. Delivery of the Shares and the Warrants at Closing. The
completion of the purchase and sale of the Shares and the Warrants (the “Closing”) shall occur on the date which is the fifth (5th) business day after the conditions set forth in this Section 3 have been satisfied or, at the Company’s discretion, on such other date within ten (10) days thereafter at a place and time (the “Closing Date”)
to be specified by the Company, and of which the Investors will be notified in advance by the Company. At the Closing, the Investor shall deliver immediately available 

  

 1. 

 
funds in the amount of the Aggregate Purchase Price by wire transfer to an account designated by the Company. At the Closing, the Company shall deliver to
the Investor, versus payment therefor, (a) one or more stock certificates representing the Shares purchased by such Investor, each such certificate to be registered in the name of the Investor or, if so indicated on the Stock Certificate and Warrant
Questionnaire attached hereto as Exhibit A, in the name of a nominee designated by the Investor and (b) the Warrant to be registered in the name of the Investor or, if so indicated on the Stock Certificate and Warrant Questionnaire
attached hereto as Exhibit A, in the name of a nominee designated by the Investor. 
  
 The Company’s obligation to issue the Shares and the Warrant to the Investor on the Closing Date shall be subject to the following conditions, any
one or more of which may be waived by the Company: (a) receipt by the Company of the Aggregate Purchase Price for the Shares and the Warrant being purchased hereunder as set forth on the Signature Page hereto; (b) receipt and acceptance by the
Company of a minimum of $10 million in aggregate subscriptions from Investors to purchase Shares and Warrants hereunder; (c) the Company shall have obtained the Required Stockholder Approval (as defined in Section 4.10); and (d) the accuracy of the
representations and warranties made by the Investors as of the Closing Date and the fulfillment of those undertakings of the Investors to be fulfilled prior to the Closing. 
  
 The Investor’s obligation to purchase the Shares and the Warrant shall be subject to the following conditions, any one
or more of which may be waived by the Investor: (a) Investors shall have executed Agreements for the purchase of Shares and Warrants representing aggregate gross proceeds to the Company of not less than $10 million; (b) the representations and
warranties of the Company contained herein shall be true and correct in all material respects as of the Closing Date as though made on and as of the Closing Date; (c) if necessary to avoid the occurrence of a “Distribution Date” under that
certain Rights Agreement dated December 11, 2002 between the Company and American Stock Transfer & Trust Company (the “Rights Agreement”), the Company shall have amended the Rights Agreement such that no Investor shall be deemed an
“Acquiring Person” under the Rights Agreement solely by virtue of the Investors receiving Securities under this Agreement; (d) the Company shall have filed a listing application with Nasdaq for the Shares and Warrant Shares; (e) the
Company shall have obtained the Required Stockholder Approval (as defined in Section 4.10); (f) there shall have been no Material Adverse Effect (as defined below) on the Company between the Definitive Agreement Date and the Closing Date; (g) total
reported revenues of the Company for its third fiscal quarter ended September 30, 2003 shall be no less than the total reported revenues of the Company for its second fiscal quarter ended June 30, 2003; and (h) the Company shall have performed,
satisfied and complied with in all material respects all covenants, agreements and conditions required to be performed, satisfied and complied with by it under the Agreement at or prior to the Closing Date. Subject to foregoing sentence, the
Investor’s obligations are expressly not conditioned on the purchase by any or all of the Other Investors of the Shares and Warrants that they have agreed to purchase from the Company. For the purposes of this Agreement, a “Material
Adverse Effect” on the Company shall mean an event, change or occurrence that individually, or together with any other event, change or occurrence, has had a material adverse impact on the Company’s financial position, business,
properties, assets, liabilities (absolute, accrued or contingent), prospects or results of operations; provided, however, that none of the direct effects of any of the following (individually or in combination) shall be deemed to constitute,
or shall be taken into account in determining whether there has been, a Material Adverse Effect on the Company: (i) changes in generally accepted accounting practices, (ii) historically experienced seasonal fluctuations in the Company’s
performance, (iii) changes in 

  

 2. 

 
worldwide general business or economic conditions affecting the industries in which the Company participates, (iv) changes in conditions generally affecting
the industries in which the Company participates, (v) the announcement or pendency of any of the transactions contemplated by this Agreement, (vi) the taking of any action required by this Agreement and (vii) expenditures by the Company in the
ordinary course of business and reasonable expenditures by the Company in connection with the transactions contemplated by this Agreement. 
  
 4. Representations, Warranties and Covenants of the Company. The Company hereby represents and warrants to, and covenants with, the
Purchasers as follows: 
  
 4.1 Organization. The
Company is duly incorporated and validly existing in good standing under the laws of the jurisdiction of its organization. The Company has full power and authority to own, operate and occupy its properties and to conduct its business as presently
conducted and is registered or qualified to do business and in good standing in each jurisdiction in which it owns or leases property or transacts business and where the failure to be so qualified would have a Material Adverse Effect on the Company.

  
 4.2 Due Authorization. The Company has all
requisite power and authority to execute, deliver and perform its obligations under the Agreements, and the Agreements have been duly authorized and validly executed and delivered by the Company and constitute legal, valid and binding agreements of
the Company enforceable against the Company in accordance with their terms, except as rights to indemnity and contribution may be limited by state or federal securities laws or the public policy underlying such laws, except as enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless
of whether such enforceability is considered in a proceeding in equity or at law). 
  
 4.3 Non-Contravention. The execution and delivery of the Agreements, the issuance and sale of the Shares and the Warrants to be sold by the Company under the Agreements, the fulfillment of the terms of
the Agreements and the consummation of the transactions contemplated thereby will not (A) conflict with or constitute a violation of, or default (with the passage of time or otherwise) under, (i) any material bond, debenture, note or other evidence
of indebtedness, or any material lease, contract, indenture, mortgage, deed of trust, loan agreement, joint venture or other agreement or instrument to which the Company is a party or by which it or its property is bound, where such conflict,
violation or default is likely to result in a Material Adverse Effect, (ii) the charter, by-laws or other organizational documents of the Company, or (iii) any law, administrative regulation, ordinance or order of any court or governmental agency,
arbitration panel or authority binding upon the Company or its property, where such conflict, violation or default is likely to result in a Material Adverse Effect, or (B) result in the creation or imposition of any lien, encumbrance, claim,
security interest or restriction whatsoever upon any of the material properties or assets of the Company or an acceleration of indebtedness pursuant to any obligation, agreement or condition contained in any material bond, debenture, note or any
other evidence of indebtedness or any material indenture, mortgage, deed of trust or any other agreement or instrument to which the Company is a party or by which it is bound or to which any of the property or assets of the Company is subject. No
consent, approval, authorization or other order of, or registration, qualification or filing with, any regulatory body, administrative agency, or other governmental body in the United States is 

  

 3. 

 
required for the execution and delivery of the Agreements and the valid issuance and sale of the Shares and the Warrants to be sold pursuant to the
Agreements, other than such as have been made or obtained, and except for any securities filings required to be made under federal or state securities laws. 
  
 4.4 Issuance, Sale and Delivery of the Shares and the Warrants. When issued and paid for in accordance with this Agreement or the applicable
form of Warrant, the Securities will be validly issued and outstanding, fully paid and non-assessable. 
  
 4.5 Additional Information. The Company represents and warrants that the information contained in the following documents, which the Company
has furnished to the Investors, or will furnish if requested by the Investor prior to the Closing, is true and correct in all material respects as of their respective filing dates: 
  
 (a) the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2002; 
  
 (b) the Company’s Quarterly Reports on Form 10-Q for the quarters
ended March 31, 2003 and June 30, 2003; and 
  
 (c) Notice
of Annual Meeting and Proxy Statement for the Company’s 2003 Annual Meeting of Stockholders. 
  
 4.6 SEC Reports. The Company has filed with the Securities and Exchange Commission (“SEC”) all reports (“SEC Reports”)
required to be filed by it under the Securities Exchange Act of 1934 (the “Exchange Act”) during the 12 months preceding the date of this Agreement. All of the SEC Reports filed by the Company comply in all material respects with the
requirements of the Exchange Act. None of the SEC Reports contains, as of the respective dates thereof, any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements
therein not misleading in light of the circumstances under which they were made. All financial statements contained in the SEC Reports have been prepared in accordance with generally accepted accounting principles consistently applied throughout the
period indicated (“GAAP”), except that unaudited financial statements are subject to normal recurring year-end audit adjustments and do not contain the footnotes required under GAAP. Each balance sheet presents fairly in accordance with
GAAP the financial position of the Company as of the date of such balance sheet, and each statement of operations, of stockholders’ equity and of cash flows presents fairly in accordance with GAAP the results of operations, the
stockholders’ equity and the cash flows of the Company for the periods then ended, in each case except that unaudited financial statements are subject to normal recurring year-end audit adjustments and do not contain the footnotes required
under GAAP. 
  
 4.7 Legal Proceedings. There is no
material legal or governmental proceeding pending to which the Company is a party or of which the business or property of the Company is subject that is not disclosed in the Company’s SEC Reports. 
  
 4.8 No Material Adverse Change. Except as disclosed in the
Company’s press releases since June 30, 2003 or other proprietary information provided to the Investor in contemplation of this Offering, as of the date hereof, there has been no Material Adverse Effect affecting the Company since the end of
the quarter for which the Company has filed its latest Quarterly Report on Form 10-Q, except that the Company continues to incur losses. 
  

 4. 

 4.9 Solvency/Indebtedness. Based on the financial condition of the Company as of the
Closing Date: (i) the fair market value of the Company’s assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known contingent liabilities) as they
mature; (ii) the Company’s assets do not constitute unreasonably small capital to carry on its business for the current fiscal year as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, and projected capital requirements and capital availability thereof; and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to
liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its debt when such amounts are required to be paid. 
  
 4.10 Vote Required. The only vote of the holders of any class
or series of the Company’s capital stock necessary to approve the Offering and the other transactions contemplated by this Agreement (the “Required Stockholder Approval”) is the affirmative vote of the majority of shares of Common
Stock present in person or represented by proxy at the Special Meeting (as defined in Section 8.1) and entitled to vote to approve the Offering. 
  
 5. Representations, Warranties and Covenants of the Investor.  
  
 5.1 The Investor represents and warrants to, and covenants with, the Company that: (i) the Investor is an
“accredited investor” as defined in Regulation D under the Securities Act of 1933, as amended (the “Securities Act”) and the Investor is also knowledgeable, sophisticated and experienced in making, and is qualified to make
decisions with respect to, investments like that involved in the purchase of the Shares, Warrant and Warrant Shares issuable upon exercise of the Warrant, including investments in securities issued by the Company and investments in comparable
companies, and has requested, received, reviewed and considered all information it deemed relevant in making an informed decision to purchase the Shares and the Warrant; (ii) the Investor is acquiring the number of Shares and the Warrant set forth
on the Signature Page hereto and any Warrant Shares it may acquire upon exercise of the Warrant in the ordinary course of its business and for its own account for investment only and with no present intention of distributing any of such Shares,
Warrant or Warrant Shares or any arrangement or understanding with any other persons regarding the distribution of such Shares, Warrant or Warrant Shares; (iii) the Investor will not, directly or indirectly, offer, sell, pledge, transfer or
otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Shares, Warrant or Warrant Shares except in compliance with the Securities Act, applicable state securities laws and the respective
rules and regulations promulgated thereunder; (iv) the Investor has answered all questions on the Signature Page hereto and the Investor Questionnaire attached hereto as Exhibit B for use in preparation of the Registration Statement
and the answers thereto are true and correct as of the date hereof and will be true and correct as of the Closing Date; (v) the Investor will notify the Company immediately of any material change in any of such information until such time as the
Investor has sold all of its Securities or until the Company is no longer required to keep the Registration Statement effective; and (vi) the Investor has, in connection with its decision to purchase the number of Shares and the Warrant set forth on
the Signature Page hereto, relied only upon the information delivered to the Investor as described in Section 4.5 above and the representations and warranties of the Company contained herein. Investor understands that its acquisition of the Shares,
the Warrant and any Warrant Shares it may acquire upon exercise of the Warrant has not been registered under the Securities Act or registered or qualified under any state securities law in 

  

 5. 

 
reliance on specific exemptions therefrom, which exemptions may depend upon, among other things, the bona fide nature of the Investor’s investment
intent as expressed herein. 
  
 5.2 The Investor
acknowledges, represents and agrees that no action has been or will be taken in any jurisdiction outside the United States by the Company, or any agents acting on behalf of the Company, that would permit an offering of the Shares, Warrant or Warrant
Shares, or possession or distribution of offering materials in connection with the issue of the Shares, Warrant or Warrant Shares, in any jurisdiction outside the United States where action for that purpose is required. Each Investor outside the
United States will comply with all applicable laws and regulations in each foreign jurisdiction in which it purchases, offers, sells or delivers Shares, Warrant or Warrant Shares or has in its possession or distributes any offering material, in all
cases at its own expense. 
  
 5.3 The Investor hereby
covenants with the Company not to make any sale of the Shares, Warrant or Warrant Shares without complying with the provisions of this Agreement, including Section 7.2 hereof, and if selling the Securities pursuant to the Registration Statement,
without effectively causing the prospectus delivery requirement under the Securities Act to be satisfied. The Investor acknowledges that the certificates evidencing the Securities and the Warrant will be imprinted with a legend that prohibits their
transfer except in accordance therewith. The Investor acknowledges that there may occasionally be times when the Company, based on the advice of its counsel, determines that it must suspend the use of the Prospectus forming a part of the
Registration Statement until such time as an amendment to the Registration Statement has been filed by the Company and declared effective by the SEC or until the Company has amended or supplemented such Prospectus. 
  
 5.4 The Investor further represents and warrants to, and covenants
with, the Company that (i) the Investor has full right, power, authority and capacity to enter into this Agreement and to consummate the transactions contemplated hereby and has taken all necessary action to authorize the execution, delivery and
performance of this Agreement, and (ii) this Agreement constitutes a valid and binding obligation of the Investor enforceable against the Investor in accordance with its terms, except as rights to indemnity and contribution may be limited by state
or federal securities laws or the public policy underlying such laws, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’
rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law). 
  
 5.5 Investor will not, prior to the effectiveness of the Registration Statement, sell, offer to sell, solicit offers
to buy, dispose of, loan, pledge or grant any right with respect to (collectively, a “Disposition”) the Securities, nor will Investor engage in any hedging or other transaction which is designed to or could reasonably be expected to lead
to or result in a Disposition of Securities by the Investor or any other person or entity. Such prohibited hedging or other transactions would include, without limitation, effecting any short sale or having in effect any short position (whether or
not such sale or position is against the box and regardless of when such position was entered into) or any purchase, sale or grant of any right (including, without limitation, any put or call option) with respect to the Securities or with respect to
any security (other than a broad-based market basket or index) that includes, relates to or derives any significant part of its value from the Securities. 
  

 6. 

 5.6 The Investor understands that nothing in this Agreement or any other materials presented to
the Investor in connection with the purchase and sale of the Shares, Warrant or Warrant Shares issuable upon exercise of the Warrant constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and investment advisors as
it, in its sole discretion, has deemed necessary or appropriate in connection with its purchase of Shares and the Warrant. 
  
 5.7 If such Investor is an individual, such Investor certifies that he or she is not, nor to his or her knowledge has been designated as, a
“suspected terrorist” as defined in Executive Order 13224. If such Investor is a corporation, trust, partnership, limited liability company or other organization, such Investor certifies that, to the best of its knowledge, such Investor
has not been designated as, and is not owned or controlled by, a “suspected terrorist” as defined in Executive Order 13224. Such Investor hereby acknowledges that the Company seeks to comply with all applicable laws covering money
laundering and related activities. In furtherance of those efforts, such Investor hereby represents, warrants and agrees that: (i) none of the cash or property that such Investor will pay or will contribute to the Company has been or shall be
derived from, or related to, any activity that is deemed criminal under United States law; and (ii) no contribution or payment by such Investor to the Company, to the extent that they are within such Investor’s control, shall cause the Company
to be in violation of the Untied States Bank Secrecy Act, the United States Money Laundering Control Act of 1986 or the Untied States International Money Laundering Abatement and Anti-Terrorist Financing Act of 2001. Such Investor shall promptly
notify the Company if any of these representations ceases to be true and accurate regarding such Investor. Such Investor agrees to provide the Company with any additional information regarding such Investor that the Company deems necessary or
convenient to ensure compliance with all applicable laws concerning money laundering and similar activities. Such Investor understands and agrees that if at any time it is discovered that any of the foregoing representations are incorrect, or if
otherwise required by applicable law or regulation related to money laundering similar activities, the Company may undertake appropriate actions to ensure compliance with applicable law or regulation, including but not limited to segregation and/or
redemption of such Investor’s investment in the Company. Such Investor further understands that the Company may release confidential information about such Investor and, if applicable, any underlying beneficial owners, to proper authorities if
the Company, in its sole discretion, determines that it is in the best interest of the Company in light of relevant rules and regulations under the laws set forth in subsection (ii) above. 
  
 6. Survival of Representations, Warranties and Agreements.
Notwithstanding any investigation made by any party to this Agreement, all covenants, agreements, representations and warranties made by the Company and the Investor herein shall survive the execution of this Agreement, the delivery to the
Investor of the Shares and the Warrant being purchased and the payment therefor. 
  
 7. Registration of the Securities; Compliance with the Securities Act.  
  
 7.1 Registration Procedures and Expenses. The Company shall:  
  
 (a) subject to receipt of necessary information from the Investors, prepare and file with the SEC, as soon as
practicable, but in no event later than thirty (30) days after the Closing Date, a registration statement on Form S-3 (the “Registration Statement”) to 

  

 7. 

 
enable the resale of the Securities by the Investors from time to time through the automated quotation system of the Nasdaq Stock Market or in
privately-negotiated transactions; 
  
 (b) use its
reasonable best efforts, subject to receipt of necessary information from the Investors, to cause the Registration Statement to become effective as soon as practicable, but in no event later than ninety (90) days after the Registration Statement is
filed by the Company; 
  
 (c) use its reasonable best
efforts to prepare and file with the SEC such amendments and supplements to the Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement current and effective for a period not
exceeding, with respect to each Investor’s Securities purchased hereunder, the earlier of (i) the second anniversary of the Closing Date, (ii) the date on which the Investor may sell all Securities then held by the Investor without restriction
by the volume limitations of Rule 144(e) of the Securities Act or (iii) such time as all Securities purchased by such Investor in this Offering have been sold pursuant to a registration statement; 
  
 (d) furnish to the Investor with respect to the Securities registered
under the Registration Statement such number of copies of the Registration Statement, Prospectuses and Preliminary Prospectuses in conformity with the requirements of the Securities Act and such other documents as the Investor may reasonably
request, in order to facilitate the public sale or other disposition of all or any of the Securities by the Investor, provided, however, that the obligation of the Company to deliver copies of Prospectuses or Preliminary Prospectuses to the
Investor shall be subject to the receipt by the Company of reasonable assurances from the Investor that the Investor will comply with the applicable provisions of the Securities Act and of such other securities or blue sky laws as may be applicable
in connection with any use of such Prospectuses or Preliminary Prospectuses; 
  
 (e) file documents required of the Company for normal blue sky clearance in states specified in writing by the Investor, provided, however, that the Company shall not be required to qualify to do
business or consent to service of process in any jurisdiction in which it is not now so qualified or has not so consented; 
  
 (f) bear all expenses in connection with the procedures in paragraph (a) through (e) of this Section 7.1 and the registration of the Securities
pursuant to the Registration Statement; and 
  
 (g) advise
the Investors, promptly after it shall receive notice or obtain knowledge of the issuance of any stop order by the SEC delaying or suspending the effectiveness of the Registration Statement or of the initiation of any proceeding for that purpose;
and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal at the earliest possible moment if such stop order should be issued. 
  
 (h) With a view to making available to the Investor the benefits of
Rule 144 (or its successor rule) and any other rule or regulation of the SEC that may at any time permit the Investor to sell Securities to the public without registration, the Company covenants and agrees to: (i) make and keep public information
available, as those terms are understood and defined in Rule 144, until the earlier of (A) such date as all of the Investor’s Securities may be resold pursuant to Rule 144(k) or any other rule of similar effect or (B) such date as all of the

  

 8. 

 
Investor’s Securities shall have been resold; (ii) file with the SEC in a timely manner all reports and other documents required of the Company under
the Securities Act and under the Exchange Act; and (iii) furnish to the Investor upon request, as long as the Investor owns any Securities, (A) a written statement by the Company that it has complied with the reporting requirements of the Securities
Act and the Exchange Act, (B) a copy of the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order to avail the Investor of any rule or
regulation of the SEC that permits the selling of any such Securities without registration. 
  
 It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 7.1 that the Investor shall furnish to the Company such information regarding itself, the Securities to
be sold by Investor, and the intended method of disposition of such securities as shall be required to effect the registration of the Securities. 
  
 The Company understands that the Investor disclaims being an underwriter, but the Investor being deemed an underwriter by the SEC shall not relieve the
Company of any obligations it has hereunder, provided, however, that if the Company receives notification from the SEC that the Investor is deemed an underwriter, then the period by which the Company is obligated to submit an acceleration
request to the SEC shall be extended to the earlier of (i) the 90th day after such SEC notification or (ii) 120 days after the initial filing of the Registration Statement with the SEC. 
  
 7.2 Transfer of Securities After Registration; Suspension.  
  
 (a) The Investor agrees that it will not effect any Disposition of
the Securities or its right to purchase the Securities that would constitute a sale within the meaning of the Securities Act except as contemplated in the Registration Statement referred to in Section 7.1, including any means of sale that would be
permissible under the Securities Act under the circumstances, and as described below, and that it will promptly notify the Company of any changes in the information set forth in the Registration Statement regarding the Investor or its plan of
distribution. 
  
 (b) Except in the event that paragraph
(c) below applies, the Company shall: (i) if deemed necessary by the Company, prepare and file from time to time with the SEC a post-effective amendment to the Registration Statement or a supplement to the related Prospectus or a supplement or
amendment to any document incorporated therein by reference or file any other required document so that such Registration Statement will not contain an untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading, and so that, as thereafter delivered to purchasers of the Securities being sold thereunder, such Prospectus will not contain an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; (ii) provide the Investor copies of any documents filed pursuant to Section
7.2(b)(i); and (iii) inform each Investor that the Company has complied with its obligations in Section 7.2(b)(i) (or that, if the Company has filed a post-effective amendment to the Registration Statement which has not yet been declared effective,
the Company will notify the Investor to that effect, will use its reasonable efforts to secure the effectiveness of such post-effective amendment as promptly as possible and will promptly notify the Investor pursuant to Section 7.2(b)(i) hereof when
the amendment has become effective). 
  

 9. 

 (c) Subject to paragraph (d) below, in the event: (i) of any request by the SEC or any other
federal or state governmental authority during the period of effectiveness of the Registration Statement for amendments or supplements to a Registration Statement or related Prospectus or for additional information; (ii) of the issuance by the SEC
or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement or the initiation of any proceedings for that purpose; (iii) of the receipt by the Company of any notification with
respect to the suspension of the qualification or exemption from qualification of any of the Securities for sale in any jurisdiction or the initiation of any proceeding for such purpose; or (iv) of any event or circumstance which necessitates the
making of any changes in the Registration Statement or Prospectus, or any document incorporated or deemed to be incorporated therein by reference, so that, in the case of the Registration Statement, it will not contain any untrue statement of a
material fact or any omission to state a material fact required to be stated therein or necessary to make the statements therein not misleading, and that in the case of the Prospectus, it will not contain any untrue statement of a material fact or
any omission to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; then the Company shall deliver a certificate in writing to
the Investor (the “Suspension Notice”) to the effect of the foregoing and, upon receipt of such Suspension Notice, the Investor will refrain from selling any Securities pursuant to the Registration Statement (a “Suspension”)
until the Investor’s receipt of copies of a supplemented or amended Prospectus prepared and filed by the Company, or until it is advised in writing by the Company that the current Prospectus may be used, and has received copies of any
additional or supplemental filings that are incorporated or deemed incorporated by reference in any such Prospectus. In the event of any Suspension, the Company will use its reasonable efforts to cause the use of the Prospectus so suspended to be
resumed as soon as reasonably practicable after delivery of a Suspension Notice to the Investors. 
  
 (d) Notwithstanding the foregoing paragraphs of this Section 7.2, the Investor shall not be prohibited from selling Securities under the
Registration Statement as a result of Suspensions on more than two occasions of not more than 30 days each in any twelve-month period, unless, in the good faith judgment of the Company’s Board of Directors, upon advice of counsel, the sale of
Securities under the Registration Statement in reliance on this paragraph 7.2(d) would be reasonably likely to cause a violation of the Securities Act or the Exchange Act and result in potential liability to the Company. 
  
 (e) Provided that a Suspension is not then in effect, the Investor
may sell Securities under the Registration Statement, provided that it arranges for delivery of a current Prospectus to the transferee of such Securities. Upon receipt of a request therefor, the Company has agreed to provide an adequate number of
current Prospectuses to the Investor and to supply copies to any other parties requiring such Prospectuses. 
  
 (f) In the event of a sale of Securities by the Investor, the Investor must also deliver to the Company’s transfer agent, with a copy to the
Company, a Certificate of Subsequent Sale substantially in the form attached hereto as Exhibit C, so that the shares may be properly transferred. 
  

7.3 Indemnification. For the purpose of this Section 7.3: 
  
 (a) the term “Selling Stockholder” shall include the Investor, any affiliate of such Investor, any Trustee
or officer of such Investor, and any investment adviser of 

  

 10. 

 
such Investor (and each person, if any, who controls such Investor or such investment adviser within the meaning of Section 15 of the Securities Act);

  
 (b) the term “Registration Statement” shall
include any final Prospectus, exhibit, supplement or amendment included in or relating to the Registration Statement referred to in Section 7.1; and 
  
 (c) the term “untrue statement” shall include any untrue statement or alleged untrue statement, or any omission or alleged omission to
state in the Registration Statement a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
  
 (i) The Company agrees to indemnify and hold harmless each Selling
Stockholder from and against any losses, claims, damages or liabilities to which such Selling Stockholder may become subject (under the Securities Act or otherwise) insofar as such losses, claims, damages or liabilities (or actions or proceedings in
respect thereof) arise out of, or are based upon (i) any untrue statement of a material fact contained in the Registration Statement, (ii) any omission of a material fact required to be stated in the Registration Statement or necessary in order to
make the statements in the Registration Statement not misleading or (iii) any failure by the Company to fulfill any undertaking included in the Registration Statement, and the Company will reimburse such Selling Stockholder for any reasonable legal
or other expenses reasonably incurred in investigating, defending or preparing to defend any such action, proceeding or claim, provided, however, that the Company shall not be liable in any such case to the extent that such loss, claim,
damage or liability arises out of, or is based upon, an untrue statement made in such Registration Statement in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Selling Stockholder
specifically for use in preparation of the Registration Statement or the failure of such Selling Stockholder to comply with its covenants and agreements contained in Sections 5.1, 5.2, 5.3 or 7.2 hereof or any misstatement or omission in any
Prospectus that is corrected in any subsequent Prospectus that was delivered to the Investor prior to the pertinent sale or sales by the Investor. 
  
 (ii) The Investor agrees to indemnify and hold harmless the Company (and each person, if any, who controls the Company within the meaning of
Section 15 of the Securities Act, each officer of the Company who signs the Registration Statement and each director of the Company) from and against any losses, claims, damages or liabilities to which the Company (or any such officer, director or
controlling person) may become subject (under the Securities Act or otherwise), insofar as such losses, claims, damages or liabilities (or actions or proceedings in respect thereof) arise out of, or are based upon, (i) any failure to comply with the
covenants and agreements contained in Section 5.1, 5.2, 5.3 or 7.2 hereof or (ii) any untrue statement of a material fact contained in the Registration Statement or any omission of a material fact required to be stated in the Registration Statement
or necessary in order to make the statements in the Registration Statement not misleading if such untrue statement or omission was made in reliance upon and in conformity with written information furnished by or on behalf of the Investor
specifically for use in preparation of the Registration Statement, and the Investor will reimburse the Company (or such officer, director or controlling person), as the case may be, for any legal or other expenses reasonably incurred in
investigating, defending or preparing to defend any such action, proceeding or claim; provided, however, that no Investor shall be required to pay any amount in excess of the gross amount received by the Investor from the sale of the
Securities to which such loss relates. 
  

 11. 

 (iii) Promptly after receipt by any indemnified person of a notice of a claim or the beginning of
any action in respect of which indemnity is to be sought against an indemnifying person pursuant to this Section 7.3, such indemnified person shall notify the indemnifying person in writing of such claim or of the commencement of such action, but
the omission to so notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party under this Section 7.3 (except to the extent that such omission materially and adversely affects the indemnifying
party’s ability to defend such action) or from any liability otherwise than under this Section 7.3. Subject to the provisions hereinafter stated, in case any such action shall be brought against an indemnified person, the indemnifying person
shall be entitled to participate therein, and, to the extent that it shall elect by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, shall be entitled to assume the defense
thereof, with counsel reasonably satisfactory to such indemnified person. After notice from the indemnifying person to such indemnified person of its election to assume the defense thereof, such indemnifying person shall not be liable to such
indemnified person for any legal expenses subsequently incurred by such indemnified person in connection with the defense thereof, provided, however, that if there exists or shall exist a conflict of interest that would make it inappropriate,
in the reasonable opinion of counsel to the indemnified person, for the same counsel to represent both the indemnified person and such indemnifying person or any affiliate or associate thereof, the indemnified person shall be entitled to retain its
own counsel at the expense of such indemnifying person; provided, however, that no indemnifying person shall be responsible for the fees and expenses of more than one separate counsel (together with appropriate local counsel) for all
indemnified parties. In no event shall any indemnifying person be liable in respect of any amounts paid in settlement of any action unless the indemnifying person shall have approved the terms of such settlement. No indemnifying person shall,
without the prior written consent of the indemnified person, effect any settlement of any pending or threatened proceeding in respect of which any indemnified person is or could have been a party and indemnification could have been sought hereunder
by such indemnified person, unless such settlement includes an unconditional release of such indemnified person from all liability on claims that are the subject matter of such proceeding. 
  
 (iv) If the indemnification provided for in this Section 7.3 is
unavailable to or insufficient to hold harmless an indemnified party under subsection (a) or (b) above in respect of any losses, claims, damages or liabilities (or actions or proceedings in respect thereof) referred to therein, then each
indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative fault
of the Company on the one hand and the Investors on the other in connection with the statements or omissions or other matters which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other
relevant equitable considerations. The relative fault shall be determined by reference to, among other things, in the case of an untrue statement, whether the untrue statement relates to information supplied by the Company on the one hand or an
Investor on the other and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such untrue statement. The Company and the Investors agree that it would not be just and equitable if contribution
pursuant to this subsection (d) were determined by pro rata allocation (even if the Investors were treated as one entity for such purpose) or by any other method of allocation which does not take into account the equitable considerations referred to
above in this subsection (d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection (d) shall be deemed to include any legal
or other 

  

 12. 

 
expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions
of this subsection (d), no Investor shall be required to contribute any amount in excess of the amount by which the gross amount received by the Investor from the sale of the Securities to which such loss relates exceeds the amount of any damages
which such Investor has otherwise been required to pay by reason of such untrue statement. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person
who was not guilty of such fraudulent misrepresentation. The Investors’ obligations in this subsection to contribute are several in proportion to their sales of Securities to which such loss relates and not joint. 
  
 (v) The parties to this Agreement hereby acknowledge that they are
sophisticated business persons who were represented by counsel during the negotiations regarding the provisions hereof including, without limitation, the provisions of this Section 7.3, and are fully informed regarding said provisions. They further
acknowledge that the provisions of this Section 7.3 fairly allocate the risks in light of the ability of the parties to investigate the Company and its business in order to assure that adequate disclosure is made in the Registration Statement as
required by the Securities Act and the Exchange Act. 
  
 7.4
Termination of Conditions and Obligations. The conditions precedent imposed by Section 5 or this Section 7 upon the transferability of the Securities shall cease and terminate as to any particular Securities when such Securities shall
have been effectively registered under the Securities Act and sold or otherwise disposed of in accordance with the intended method of disposition set forth in the Registration Statement covering such Securities or at such time as an opinion of
counsel satisfactory to the Company shall have been rendered to the effect that such conditions are not necessary in order to comply with the Securities Act. 
  
 7.5 Information Available. So long as the Registration Statement is effective covering the resale of Securities owned by the Investor, the
Company will furnish or make available to the Investor: 
  
 (a) as soon as practicable after it is available, one copy of (i) its Annual Report to Stockholders (which Annual Report shall contain financial statements audited in accordance with generally accepted accounting principles by a
national firm of certified public accountants) and (ii) if not included in substance in the Annual Report to Stockholders, its Annual Report on Form 10-K (the foregoing, in each case, excluding exhibits); 
  
 (b) upon the reasonable request of the Investor, all exhibits
excluded by the parenthetical to subparagraph (a)(ii) of this Section 7.5 as filed with the SEC and all other information that is made available to stockholders; and 
  
 (c) upon the reasonable request of the Investor, an adequate number of copies of the Prospectuses to supply to any
other party requiring such Prospectuses. 
  
 7.6
Liquidated Damages. In the event that the Registration Statement is not declared effective within one hundred twenty (120) days after the Closing Date (the “Event Date”), the Company shall pay to each Investor 1.0% of such
Investor’s Aggregate Purchase Price per month (on a pro-rated basis) for the period commencing on the day after the Event Date and ending on the date the Registration Statement is declared effective. In addition, the 

  

 13. 

 
Company shall pay to each Investor 1.0% of such Investor’s Aggregate Purchase Price per month (on a pro-rated basis), for each month that a Suspension
is imposed in excess of the allowable time period for such Suspensions as identified in Section 7.2(d). 
  
 8. Covenants of the Company 
  
 8.1 The Company shall use its commercially reasonable efforts to call a special meeting of its stockholders (the “Special Meeting”), to
be held within forty-five (45) days after the Definitive Agreement Date, and shall solicit at such Special Meeting all necessary or appropriate approvals of the stockholders, including without limitation, as may be required pursuant to the Nasdaq
Marketplace Rules, with respect to (i) the transactions contemplated by the Agreements; and (ii) any other matters as may properly be brought before such Special Meeting; provided, however, that if due to the SEC review of the Company’s
preliminary proxy statement filed in connection with the Special Meeting or any other delay due to unforeseen circumstances, the Special Meeting is not held within such forty-five (45) days after the Definitive Agreement Date, the Company shall use
its commercially reasonable efforts to hold such Special Meeting as soon as thereafter reasonably practicable, and such delay shall not constitute a material breach of this Agreement or relieve the Investors from their obligations to purchase the
Shares and the Warrants as otherwise set forth in and would be required by the Agreements. The Company shall prepare and file with the SEC a proxy statement meeting the requirements of Section 14 of the Securities Exchange Act of 1934, as amended,
and the related rules and regulations thereunder promulgated by the SEC (the “Proxy Statement”) to solicit the Required Stockholder Approval. The Company shall use its commercially reasonable efforts to cause the Proxy Statement to be
cleared by the SEC as promptly as reasonably practicable after such filing, and shall promptly mail the Proxy Statement to the stockholders of the Company. The Company shall keep the Investors apprised of the status of matters relating to the Proxy
Statement and the Special Meeting, including promptly furnishing the Investors and their counsel with copies of notices or other communications related to the Proxy Statement, the Special Meeting or the transactions contemplated hereby received by
the Company from the SEC or Nasdaq. 
  
 8.2 After the
Definitive Agreement Date, the Company shall not, without the prior written consent of the Initial Investors representing a majority of the total Aggregate Purchase Prices to be paid by all such Initial Investors, enter into any agreement with any
Investor (other than the Initial Investors) that would grant such Investor under such agreement a Warrant to purchase a number of Warrant Shares greater than the quotient of 60% of such Investor’s Aggregate Purchase Price for such Investor
under such agreement divided by the Purchase Price under such agreement. 
  
 8.3 After the receipt and acceptance by the Company of a minimum of $10 million in aggregate subscriptions from Investors to purchase Shares and Warrants hereunder, the Company shall offer to each of the
Initial Investors a right to subscribe for additional Shares and Warrants for an aggregate purchase price equal to its pro rata portion, as defined below, of all subscriptions received and accepted by the Company in the Offering over and
above $10 million in the aggregate (such amount referred to herein as the “Excess Subscription Amount”). Each Initial Investor’s pro rata portion is equal to such portion of the Excess Subscription Amount equal to the
proportion of the Aggregate Purchase Price under the Agreement executed by such Initial Investor on the Definitive Agreement Date to the aggregate of all Aggregate Purchase Prices under the Agreements executed by all Initial Investors on the
Definitive 

  

 14. 

 
Agreement Date. When the Company has received and accepted subscriptions hereunder for an Excess Subscription Amount, it shall give each Initial Investor
notice of such fact and the actual amount of such Excess Subscription Amount. After its receipt of such notice, each Initial Investor shall promptly notify the Company whether or not it intends to subscribe for its pro rata portion of the
Excess Subscription Amount and, if such Initial Investor affirmatively elects to exercise this right, such Initial Investor shall promptly enter into an agreement, in the same form as the Agreement executed by such Initial Investor on the Definitive
Agreement Date, subscribing for such additional Shares and Warrants for a Purchase Price equal to the Reference Price. If not all of the Initial Investors elect to subscribe for their pro rata portion of the Excess Subscription Amount, then
the Company shall promptly notify the Initial Investors who do so elect and shall offer such Initial Investors the right to subscribe for such unsubscribed amounts. Notwithstanding the foregoing provisions of this Section 8.3, the Company
shall not be required to accept subscriptions from the Initial Investors after the Definitive Agreement Date that would result in aggregate subscriptions in the Offering exceeding $14 million, and in such case, the Initial Investors shall have a
right to subscribe for their respective pro rata portions of only the amount by which $14 million exceeds the Excess Subscription Amount plus $10 million. 
  
 9. Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be
mailed (A) if within domestic United States by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, or by facsimile, or (B) if delivered from outside the United States, by International
Federal Express or facsimile, and shall be deemed given (i) if delivered by first-class registered or certified mail domestic, three business days after so mailed, (ii) if delivered by nationally recognized overnight carrier, one (1) business day
after so mailed, (iii) if delivered by International Federal Express, two (2) business days after so mailed, (iv) if delivered by facsimile, upon electric confirmation of receipt and shall be delivered as addressed as follows: 
  
 (a)     if to the Company, to: 

 
           HealtheTech,
Inc. 
           523 Park Point Drive, 3rd Floor 
           Golden, Colorado 80401 
           Attn: Chief Executive Officer 
           Facsimile: (303) 526-5186 
  
 (b)     with a copy mailed to: 
  

          Cooley Godward LLP 
           380 Interlocken Crescent, Suite 900 
           Broomfield, Colorado 80021 
           Attn: Michael Platt 
           Facsimile: (720) 566-4099 
  
 (c) if to the Investor, at its address on the Signature Page hereto, or at such other address or addresses as may
have been furnished to the Company in writing. 
  
 10.
Changes. This Agreement may not be modified or amended except pursuant to an instrument in writing signed by the Company and the Investor. 
  

 15. 

 11. Headings. The headings of the various sections of this Agreement have been inserted for
convenience of reference only and shall not be deemed to be part of this Agreement. 
  
 12. Severability. In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions
contained herein shall not in any way be affected or impaired thereby. 
  
 13. Governing Law. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Colorado, without giving effect to the principles of conflicts of law. 
  
 14. Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the
other parties. 
  
 15. Non-Public Information. The
Company covenants and agrees that neither it nor any other person acting on its behalf will provide the Investor or its agents or counsel with any information that the Company believes constitutes material non-public information, unless prior
thereto the Investor shall have executed a written agreement regarding the confidentiality and use of such information. The Company understands and confirms that the Investor shall be relying on the foregoing sentence in effecting transactions in
securities of the Company. 
  
 16. Confidential
Disclosure Agreement. Notwithstanding any provision of this Agreement to the contrary, any confidential disclosure agreement previously executed by the Company and the Investor in connection with the transactions contemplated by this Agreement
shall remain in full force and effect in accordance with its terms following the execution of this Agreement and the consummation of the transactions contemplated hereby. 
  
 17. Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor hereunder
is several and not joint with the obligations of any other Investor hereunder, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor hereunder. Nothing contained herein or in any other agreement
or document delivered at any closing, and no action taken by any Investor pursuant hereto or thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption
that the Investors are in any way acting in concert with respect to such obligations or the transactions contemplated by this Agreement. Each Investor shall be entitled to protect and enforce its rights, including without limitation the rights
arising out of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. Each Investor has been represented by its own separate legal counsel in their review and
negotiation of the Agreements. For reasons of administrative convenience only, the Investors and their respective counsel may have chosen to communicate with the Company through one counsel. 
  
 18. Expenses. The Company shall pay all costs and expenses that
it incurs with respect to the negotiation, execution, delivery and performance of the Agreements and the transactions contemplated thereby. The Company shall, following the Closing, reimburse the reasonable fees of and expenses of one special
counsel for Investors. 
  

 16. 

 19. Tax Disclosure. Notwithstanding any provision of this Agreement to the contrary, any
party to this Agreement (and any employee, representative, shareholder or other agent of any party to this Agreement) may disclose to any and all persons, without limitation of any kind, the tax treatment and tax structure of the transactions
contemplated by this Agreement and all materials of any kind (including opinions or other tax analyses) that are provided to it relating to such tax treatment and tax structure; provided however, that such disclosure may not be made to the
extent reasonably necessary to comply with any applicable federal or state securities laws; and provided further, that for this purpose, (a) the “tax treatment” of a transaction means the purported or claimed federal
income tax treatment of the transaction and (b) the “tax structure” of a transaction means any fact that may be relevant to understanding the purported or claimed federal income tax treatment of the transaction. 

 

 17. 

 EXHIBIT A 
  
 HEALTHETECH, INC. 
  
 STOCK CERTIFICATE AND WARRANT QUESTIONNAIRE 
  
 Pursuant to Section 3 of the Terms and Conditions for Purchase of Securities, please provide us with the following information: 
  

			
	 1.      
	 	The exact name that your Shares and Warrant are to be registered in (this is the name that will appear on your stock certificate(s) and Warrant). You may use a nominee name if
appropriate:	 	

			
	 2.
	 	The relationship between the Investor and the registered holder listed in response to item 1 above:	 	

			
	 3.
	 	The mailing address of the registered holder listed in response to item 1 above:	 	

			
	 4.
	 	The Social Security Number or Tax Identification Number of the registered holder listed in the response to item 1 above:	 	

  
  

 A-1 

 EXHIBIT B 
  
 HEALTHETECH, INC. 
  
 INVESTOR QUESTIONNAIRE 
  
 (all information will be treated confidentially) 
  
 To: Investor 
  
 This Investor Questionnaire (“Questionnaire”) must be completed by each potential investor in connection with the offer and sale of the shares
of the common stock, par value $0.001 per share, of HealtheTech, Inc. (the “Common Stock”) and warrants to purchase shares of the Common Stock (collectively with the Common Stock, the “Securities”). The Securities are being
offered and sold by HealtheTech, Inc. (the “Corporation”) without registration under the Securities Act of 1933, as amended (the “Act”) and the securities laws of certain states, in reliance on the exemptions contained in Section
4(2) of the Act and Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state laws. The Corporation must determine that a potential investor meets certain suitability requirements before offering or selling
Securities to such investor. The purpose of this Questionnaire is to assure the Corporation that each investor will meet the applicable suitability requirements. The information supplied by you will be used in determining whether you meet such
criteria, and reliance upon the private offering exemption from registration is based in part on the information herein supplied. 
  
 This Questionnaire does not constitute an offer to sell or a solicitation of an offer to buy any security. Your answers will be kept strictly
confidential. However, by signing this Questionnaire, you will be authorizing the Corporation to provide a completed copy of this Questionnaire to such parties as the Corporation deems appropriate in order to ensure that the offer and sale of the
Securities will not result in a violation of the Act or the securities laws of any state and that you otherwise satisfy the suitability standards applicable to purchasers of the Securities. All potential investors must answer all applicable
questions and complete, date and sign this Questionnaire. Please print or type your responses and attach additional sheets of paper if necessary to complete your answers to any item. 
  
 A. BACKGROUND INFORMATION 
  

	
	 Name:                                     
                                        
                                        
                                        
                                        
                                        
       

	
	 Business
Address:                                      
                                        
                                        
                                        
                                        
                       

	
	(Number and Street)
	
	                                       
                                        
                                        
                                        
                                        
                                        
                  

			
	 (City)
	  	               (State)
	 	               (Zip Code)

	
	 Telephone Number:
(            )                           
                                        
                                        
                                        
                                        
             

	
	 Residence
Address:                                      
                                        
                                        
                                        
                                        
                     

	
	 (Number and Street)
  
 ___________________________________________________________________________________________________________

			
	 (City)
	  	               (State)
	 	               (Zip Code)

	
	 Telephone Number:
(            )                           
                                        
                                        
                                        
                                        
             

	
	 If an individual:

			
	 Age:            
	  	 Citizenship:            
	 	 Where
registered to vote:                                  
   

	
	 If a corporation, partnership, limited liability company, trust or other entity:

	
	 Type of
entity:                                       
                                        
                                        
                                        
                                        
                             

			
	 State of
formation:                        
	  	 	 	 Date of
formation:                                      
           

	
	 Social Security or Taxpayer Identification
No.                                       
                                        
                                        
                                        
          

  

 B-1 

	 Send all correspondence to (check one): 
             Residence Address
	 	             Business Address

  
 B. STATUS
AS ACCREDITED INVESTOR 
  
 The
undersigned is an “accredited investor” as such term is defined in Regulation D under the Act, as at the time of the sale of the Securities the undersigned falls within one or more of the following categories (Please initial one or more,
as applicable):1 
  
             (1) a bank, as defined in Section 3(a)(2) of the Act, or a savings and loan association or
other institution as defined in Section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; a broker or dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934; an insurance company as defined in
Section 2(13) of the Act; an investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that Act; a Small Business Investment Corporation licensed by the U.S. Small
Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions for
the benefit of its employees, if such plan has total assets in excess of $5,000,000; an employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as
defined in Section 3(21) of such Act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan,
with the investment decisions made solely by persons that are accredited investors; 
  
             (2) a private business development company as defined in Section 202(a)(22) of the Investment Adviser Act of 1940; 
  
             (3) an
organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the Securities offered, with total
assets in excess of $5,000,000; 
  
             (4) a director, executive officer, or general partner of the issuer of the Securities being offered or sold, or any director, executive officer, or general
partner of a general partner of that issuer; 
  
             (5) a natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of such person’s purchase of the Securities
exceeds $1,000,000; 
  
             (6) a natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person’s spouse in
excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year; 
  
             (7) a trust, with total assets in excess of $5,000,000, not formed for the specific purpose
of acquiring the Securities offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D; and 
  
             (8) an entity in which all of the equity owners are accredited investors (as defined
above). 

	1	As used in this Questionnaire, the term “net worth” means the excess of total assets over total liabilities. In computing net worth for the purpose of
subsection (5), the principal residence of the investor must be valued at cost, including cost of improvements, or at recently appraised value by an institutional lender making a secured loan, net of encumbrances. In determining income, the investor
should add to the investor’s adjusted gross income any amounts attributable to tax exempt income received, losses claimed as a limited partner in any limited partnership, deductions claimed for depiction, contributions to an IRA or KEOGH
retirement plan, alimony payments, and any amount by which income from long-term capital gains has been reduced in arriving at adjusted gross income. 

  

 B-2 

 C. REPRESENTATIONS 
  
 The undersigned hereby represents and warrants to the Corporation as follows: 
  
 1. Any purchase of the Securities would be solely for the account of the undersigned and not for the account of any
other person or with a view to any resale, fractionalization, division, or distribution thereof. 
  
 2. The information contained herein is complete and accurate and may be relied upon by the Corporation, and the undersigned will notify the
Corporation immediately of any material change in any of such information occurring prior to the closing, if any, with respect to the purchase of Securities by the undersigned or any co-purchaser. 
  
 3. There are no suits, pending litigation, or claims against the
undersigned that could materially affect the net worth of the undersigned as reported in this Questionnaire. 
  
 4. The undersigned acknowledges that there may occasionally be times when the Corporation, based on the advice of its counsel, determines that it
must suspend the use of the Prospectus forming a part of the Registration Statement (as such terms are defined in the Securities Purchase Agreement to which this Questionnaire is attached) until such time as an amendment to the Registration
Statement has been filed by the Corporation and declared effective by the Securities and Exchange Commission or until the Corporation has amended or supplemented such Prospectus. The undersigned is aware that, in such event, the Securities will not
be subject to ready liquidation, and that any Securities purchased by the undersigned would have to be held during such suspension. The overall commitment of the undersigned to investments which are not readily marketable is not excessive in view of
the undersigned’s net worth and financial circumstances, and any purchase of the Securities will not cause such commitment to become excessive. The undersigned is able to bear the economic risk of an investment in the Securities. 
  
 5. In addition to reviewing the Corporation’s Offering Materials
(as such term is defined in the Securities Purchase Agreement to which this Questionnaire is attached), the undersigned has carefully considered the potential risks relating to the Corporation and a purchase of the Securities, and fully understands
that the Securities are speculative investments which involve a high degree of risk of loss of the undersigned’s entire investment. Among others, the undersigned has carefully considered each of the risks described under the heading “Risks
Factors” in the Corporation’s most recent annual report on Form 10-K and quarterly report on Form 10-Q. 
  
 IN WITNESS WHEREOF, the undersigned has executed this Questionnaire this              day of September
2003, and declares under oath that it is truthful and correct. 
  

	
	 Investor:_____________________________________

	
	 By:__________________________________________

	
	 Print Name:____________________________________

	
	 Title:_________________________________________

	 (required for any purchaser that is a corporation, partnership, trust or other entity)

  
  
  

 B-3 

 EXHIBIT C 
  
 HEALTHETECH, INC. 
  
 CERTIFICATE OF SUBSEQUENT SALE 
  
 American Stock Transfer & Trust Company 
 6210 15th Avenue 
 Brooklyn, New York 11219 
 718-921-8380 
  

	 	RE:	Sale of Shares of Common Stock of HealtheTech, Inc. (the “Company”) pursuant to the Company’s Prospectus dated
            , 2003 (the “Prospectus”) 

  
 Dear Sir/Madam: 
  
 The undersigned hereby certifies, in connection with the sale of shares of Common Stock of the Company included in the table of Selling Stockholders in
the Prospectus, that the undersigned has sold such shares pursuant to the Prospectus and in a manner described under the caption “Plan of Distribution” in the Prospectus and that such sale complies with all applicable securities laws,
including, without limitation, the Prospectus delivery requirements of the Securities Act of 1933, as amended. 
  

	 Selling Stockholder (the beneficial
owner):                                       
                                        
                                        
                                        
      

	
	 Record Holder (e.g., if held in name of
nominee):                                      
                                        
                                        
                                   

	
	 Restricted Stock Certificate
No.(s):                                       
                                        
                                        
                                        
                     

	
	 Number of Shares
Sold:                                       
                                        
                                        
                                        
                                        
  

	
	 Date of
Sale:                                       
                                        
                                        
                                        
                                        
                       

  
 In the event that you
receive a stock certificate(s) representing more shares of Common Stock than have been sold by the undersigned, then you should return to the undersigned a newly issued certificate for such excess shares in the name of the Record Holder and BEARING
A RESTRICTIVE LEGEND. Further, you should place a stop transfer on your records with regard to such certificate. 
  

	 	 	 	 	 Very truly yours,

				
	 	 	 	 	 	 	 By:___________________________________________

				
	 	 	 	 	 	 	 Print Name:_____________________________________

			
	 Dated:
                        
	 	 	 	 Title:__________________________________________

  

	cc:	Chief Financial Officer 

 HealtheTech, Inc. 
 523 Park Point Drive, 3rd Floor 
 Golden, Colorado 80401 
  

 C-1 

 ANNEX II 
  

WARRANTCommon Stock Warrant

 Exhibit 10.53 
  
 THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”). SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF REGISTRATION OR AN EXEMPTION THEREFROM. HEALTHETECH, INC. MAY REQUIRE AN OPINION OF COUNSEL REASONABLY ACCEPTABLE TO IT THAT A PROPOSED TRANSFER OR SALE
IS IN COMPLIANCE WITH THE ACT. 
  
 HEALTHETECH, INC.

  
 COMMON STOCK PURCHASE WARRANT 
  

	Warrant No. CS-[            ]	 	             Shares
	             , 2003
	 	 

  
 1. Issuance.
For value received, this Warrant is issued to [HOLDER], by HEALTHETECH, INC., a Delaware corporation (hereinafter with its successors called the “Company”),
pursuant to the terms of that certain Securities Purchase Agreement dated             , 2003. 
  

2. Purchase Price; Number of Shares. The registered holder of this Warrant (the “Holder”), commencing on the date hereof, is
entitled upon surrender of this Warrant with the subscription form annexed hereto duly executed, at the principal office of the Company, to purchase from the Company [            
(            )] fully paid and nonassessable shares (the “Shares”) of common stock, $.001 par value per share, of the Company (the “Common Stock”),
at a price per share of $[            ] (the “Purchase Price”). Until such time as this Warrant is exercised in full or expires, the Purchase Price and the
securities issuable upon exercise of this Warrant are subject to adjustment as hereinafter provided. The person or persons under whose name or names any certificate representing shares of Common Stock is issued hereunder shall be deemed to have
become the holder of record of the shares represented thereby as at the close of business on the date this Warrant is exercised with respect to such shares, whether or not the transfer books of the Company shall be closed. 
  
 3. Payment of Purchase Price. The Purchase Price may be paid (i) in
cash or by check; (ii) by the surrender by the Holder to the Company of any promissory notes or other obligations issued by the Company, with all such notes and obligations so surrendered being credited against the Purchase Price in an amount equal
to the principal amount thereof plus accrued interest to the date of surrender; or (iii) by any combination of the foregoing. 
  
 4. Net Issue Election. The Holder may elect to receive, without the payment by the Holder of any additional consideration, shares of Common
Stock equal to the value of this Warrant or any portion hereof by the surrender of this Warrant or such portion to the Company, with the net issue election notice annexed hereto duly executed, at the principal office of the 

  

 1. 

 
Company. Thereupon, the Company shall issue to the Holder such number of fully paid and nonassessable shares of Common Stock as is computed using the
following formula: 
  
  

	 	  	 	  	 X =
	  	Y (A-B)	  	 
	 	  	 	  	  	    A    	  	 
	 where:
	  	X =	  	 the number of shares of Common Stock to be issued to the Holder pursuant to this Section 4.

	 	  	Y =	  	 the number of shares of Common Stock covered by this Warrant in respect of which the net issue election is made pursuant
to this Section 4.

	 	  	A =	  	 the Fair Market Value (defined below) of one share of Common Stock, as determined at the time the net issue election is
made pursuant to this Section 4.

	 	  	B =	  	 the Purchase Price per Share in effect under this Warrant at the time the net issue election is made pursuant to this
Section 4.

  
 “Fair Market Value” of a
share of Common Stock as of a particular date (the “Determination Date”) shall mean the average of the closing or last reported sale prices of the Common Stock as reported on the Nasdaq National Market over the 30-day period ending five
business days prior to the Determination Date; provided, however, that if (i) the Common Stock is neither traded on the Nasdaq National Market nor on a national securities exchange, then Fair Market Value shall be the average of the closing
or last reported sale prices of the Common Stock over the 30-day period ending five business days prior to the Determination Date reflected in the over-the-counter market, as reported by the National Quotation Bureau, Inc. or any organization
performing a similar function, or if closing prices are not then routinely reported for the over-the-counter market, the average of the last bid and asked prices of the Common Stock over the 30-day period ending five business days prior to the
Determination Date and (ii) if there is no public market for the Common Stock, then Fair Market Value shall be determined in good faith by the Company’s Board of Directors. 
  
 5. Partial Exercise. This Warrant may be exercised in part, and the Holder shall be entitled to receive a new
warrant, which shall be dated as of the date of this Warrant, covering the number of shares in respect of which this Warrant shall not have been exercised. 
  
 6. Fractional Shares. In no event shall any fractional share of Common Stock be issued upon any exercise of this Warrant. If, upon exercise of this
Warrant as an entirety, the Holder would, except as provided in this Section 6, be entitled to receive a fractional share of Common Stock, then the Company shall pay in lieu thereof, the Fair Market Value of such fractional share in cash.

  
 7. Expiration Date; Early Termination. 
  

 2. 

 (a) Except as otherwise set forth in this Section 7, this Warrant shall expire on the close of
business on                          , 2013 (the “Expiration Date”), and shall be void thereafter. 

 
 (b) In the event of, at any time prior to the Expiration Date, any
capital reorganization, or any reclassification of the capital stock of the Company (other than as a result of a stock dividend or subdivision, split-up or combination of shares), or the consolidation or merger of the Company with or into another
corporation, or the sale or other disposition of all or substantially all the properties and assets of the Company in its entirety to any other person, the Company shall provide to the Holder fifteen (15) days advance written notice of such public
offering, reorganization, reclassification, consolidation, merger or sale or other disposition of the Company’s assets, and this Warrant shall terminate unless exercised prior to the occurrence of such reorganization, reclassification,
consolidation, merger or sale or other disposition of the Company’s assets. 
  
 8. Reserved Shares; Valid Issuance. The Company covenants that it will at all times from and after the date hereof reserve and keep available such number of its authorized shares of Common Stock, free from all
preemptive or similar rights therein, as will be sufficient to permit the exercise of this Warrant in full into shares of Common Stock upon such exercise. The Company further covenants that such shares as may be issued pursuant to such exercise
will, upon issuance, be duly and validly issued, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issuance thereof. 
  

9. Adjustment of Purchase Price and Number of Shares. 
  

(a) Stock Splits and Dividends. If after the date hereof the Company shall subdivide the Common Stock, by split-up or otherwise, or combine the
Common Stock, or issue additional shares of Common Stock in payment of a stock dividend on the Common Stock, the number of shares of Common Stock issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a
subdivision or stock dividend, or proportionately decreased in the case of a combination, and the Purchase Price shall forthwith be proportionately decreased in the case of a subdivision or stock dividend, or proportionately increased in the case of
a combination. 
 (b) Sale of Shares Below Purchase Price. 
  
 (i) If after the date hereof the Company issues or sells, or is deemed by the express provisions of this Section 9(b) to
have issued or sold, Additional Shares of Common Stock (as defined below), other than as provided in Section 9(a) above, for an Effective Price (as defined below) less than the then effective Purchase Price (a “Qualifying Dilutive
Issuance”), then and in each such case, the then existing Purchase Price shall be reduced, as of the opening of business on the date of such issue or sale, to a price determined by multiplying the Purchase Price in effect immediately prior to
such issuance or sale by a fraction equal to: 
  
 (A) the
numerator of which shall be (A) the number of shares of Common Stock deemed outstanding (as determined below) immediately prior to such issue or sale, plus (B) the number of shares of Common Stock which the Aggregate Consideration (as 

  

 3. 

 
defined below) received by the Company for the total number of Additional Shares of Common Stock so issued would purchase at such then-existing Purchase
Price, and 
  
 (B) the denominator of which shall be the number
of shares of Common Stock deemed outstanding (as determined below) immediately prior to such issue or sale plus the total number of Additional Shares of Common Stock so issued. 
  
 For the purposes of the preceding sentence, the number of shares of Common Stock deemed to be outstanding as of a given date
shall be the sum of (A) the number of shares of Common Stock outstanding, and (B) the number of shares of Common Stock which could be obtained through the exercise or conversion of all other rights, options and convertible securities outstanding on
the day immediately preceding the given date. 
  
 (ii) No
adjustment shall be made to the Purchase Price in an amount less than five cents per share. Any adjustment otherwise required by this Section 9(b) that is not required to be made due to the preceding sentence shall be included in any subsequent
adjustment to the Purchase Price. 
  
 (iii) For the purpose of
making any adjustment required under this Section 9(b), the aggregate consideration received by the Company for any issue or sale of securities (the “Aggregate Consideration”) shall be defined as: (A) to the extent it consists of cash, be
computed at the net amount of cash received by the Company after deduction of any underwriting or similar commissions, compensation or concessions paid or allowed by the Company in connection with such issue or sale but without deduction of any
expenses payable by the Company, (B) to the extent it consists of property other than cash, be computed at the fair value of that property as determined in good faith by the Board, and (C) if Additional Shares of Common Stock, Convertible Securities
(as defined below) or rights or options to purchase either Additional Shares of Common Stock or Convertible Securities are issued or sold together with other stock or securities or other assets of the Company for a consideration which covers both,
be computed as the portion of the consideration so received that may be reasonably determined in good faith by the Board to be allocable to such Additional Shares of Common Stock, Convertible Securities or rights or options. 
  
 (iv) For the purpose of the adjustment required under this Section 9(b), if
the Company issues or sells (x) Preferred Stock or other stock, options, warrants, purchase rights or other securities convertible into, Additional Shares of Common Stock (such convertible stock or securities being herein referred to as
“Convertible Securities”) or (y) rights or options for the purchase of Additional Shares of Common Stock or Convertible Securities, and if the Effective Price of such Additional Shares of Common Stock is less than the Purchase Price, in
each case the Company shall be deemed to have issued at the time of the issuance of such rights or options or Convertible Securities the maximum number of Additional Shares of Common Stock issuable upon exercise or conversion thereof and to have
received as consideration for the issuance of such shares an amount equal to the total amount of the consideration, if any, received by the Company for the issuance of such rights or options or Convertible Securities plus: 
  

 4. 

 (A) in the case of such rights or options, the minimum amounts of consideration, if any, payable to the
Company upon the exercise of such rights or options; and 
  
 (B)
in the case of Convertible Securities, the minimum amounts of consideration, if any, payable to the Company upon the conversion thereof (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities);
provided that if the minimum amounts of such consideration cannot be ascertained, but are a function of antidilution or similar protective clauses, the Company shall be deemed to have received the minimum amounts of consideration without
reference to such clauses. 
  
 If the minimum amount of
consideration payable to the Company upon the exercise or conversion of rights, options or Convertible Securities is reduced over time or on the occurrence or non-occurrence of specified events other than by reason of antidilution adjustments, the
Effective Price shall be recalculated using the figure to which such minimum amount of consideration is reduced; provided further, that if the minimum amount of consideration payable to the Company upon the exercise or conversion of such
rights, options or Convertible Securities is subsequently increased, the Effective Price shall be again recalculated using the increased minimum amount of consideration payable to the Company upon the exercise or conversion of such rights, options
or Convertible Securities. 
  
 No further adjustment of the
Purchase Price, as adjusted upon the issuance of such rights, options or Convertible Securities, shall be made as a result of the actual issuance of Additional Shares of Common Stock or the exercise of any such rights or options or the conversion of
any such Convertible Securities. If any such rights or options or the conversion privilege represented by any such Convertible Securities shall expire without having been exercised, the Purchase Price as adjusted upon the issuance of such rights,
options or Convertible Securities shall be readjusted to the Purchase Price which would have been in effect had an adjustment been made on the basis that the only Additional Shares of Common Stock so issued were the Additional Shares of Common
Stock, if any, actually issued or sold on the exercise of such rights or options or rights of conversion of such Convertible Securities, and such Additional Shares of Common Stock, if any, were issued or sold for the consideration actually received
by the Company upon such exercise, plus the consideration, if any, actually received by the Company for the granting of all such rights or options, whether or not exercised, plus the consideration received for issuing or selling the Convertible
Securities actually converted, plus the consideration, if any, actually received by the Company (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities) on the conversion of such Convertible Securities.

  
 (v) For the purpose of making any adjustment to the Purchase
Price required under this Section 9(b), “Additional Shares of Common Stock” shall mean all shares of Common Stock issued by the Company or deemed to be issued pursuant to this Section 9(b) (including shares of Common Stock subsequently
reacquired or retired by the Company), other than: 
  
 (A) shares
of Common Stock or Convertible Securities issued after the date hereof to employees, officers or directors of, or consultants or advisors to the 

  

 5. 

 
Company or any subsidiary pursuant to stock purchase or stock option plans or other arrangements that are approved by the Board; 
  
 (B) shares of Common Stock issued pursuant to the exercise and/or conversion
of (x) Convertible Securities outstanding as of the date hereof or (y) Convertible Securities issued pursuant to any of subsections (A) through (F) of this clause (v); 
  
 (C) shares of Common Stock or Convertible Securities issued for consideration other than cash pursuant to a merger,
consolidation, acquisition, strategic alliance or similar business combination approved by the Board; 
  
 (D) shares of Common Stock or Convertible Securities issued pursuant to any equipment loan or leasing arrangement, real property leasing arrangement or
debt financing from a bank or similar financial institution approved by the Board; 
  
 (E) shares of Common Stock or Convertible Securities issued to third-party service providers in exchange for or as partial consideration for services rendered to the Company; and 
  
 (F) shares of Common Stock or Convertible Securities issued in connection
with strategic transactions involving the Company and other entities, including (i) joint ventures, manufacturing, marketing or distribution arrangements or (ii) technology transfer or development arrangements; provided that the issuance of
shares therein has been approved by the Company’s Board. 
  
 References to Common Stock in the subsections of this clause (v) above shall mean all shares of Common Stock issued by the Company or deemed to be issued pursuant to this Section 9(b). The “Effective Price” of Additional Shares of
Common Stock shall mean the quotient determined by dividing the total number of Additional Shares of Common Stock issued or sold, or deemed to have been issued or sold by the Company under this Section 9(b), into the Aggregate Consideration
received, or deemed to have been received by the Company for such issue under this Section 9(b), for such Additional Shares of Common Stock. 
  
 (vi) In the event that the Company issues or sells, or is deemed to have issued or sold, Additional shares of Common Stock in a Qualifying Dilutive
Issuance (the “First Dilutive Issuance”), then in the event that the Company issues or sells, or is deemed to have issued or sold, Additional Shares of Common Stock in a Qualifying Dilutive Issuance other than the First Dilutive Issuance
pursuant to the same instruments as the First Dilutive Issuance (a “Subsequent Dilutive Issuance”), then and in each such case upon a Subsequent Dilutive Issuance the Purchase Price shall be reduced to the Purchase Price that would have
been in effect had the First Dilutive Issuance and each Subsequent Dilutive Issuance all occurred on the closing date of the First Dilutive Issuance. 
  
 (c) Certificate of Adjustment. In each case of an adjustment or readjustment of the Purchase Price, the Company, at its expense, shall compute such
adjustment or readjustment in accordance with the provisions hereof and prepare a certificate showing such 

  

 6. 

 
adjustment or readjustment, and shall mail such certificate, by first class mail, postage prepaid, to the Holder at the Holder’s address as shown in the
Company’s books. The certificate shall set forth such adjustment or readjustment, showing in detail the facts upon which such adjustment or readjustment is based, including a statement of (i) the consideration received or deemed to be received
by the Company for any Additional Shares of Common Stock issued or sold or deemed to have been issued or sold, (ii) the Purchase Price at the time in effect, and (iii) the number of Additional Shares of Common Stock. 
  
 10. Notices of Record Date, Etc. In the event of: 

 
 (a) any taking by the Company of a record of the holders of any
class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, or any right to subscribe for, purchase, sell or otherwise acquire or dispose of any shares of stock of any class
or any other securities or property, or to receive any other right; 
  
 (b) any reclassification of the capital stock of the Company, capital reorganization of the Company, consolidation or merger involving the Company, or sale or conveyance of all or substantially all of its assets; or 
  
 (c) any voluntary or involuntary dissolution, liquidation or
winding-up of the Company; 
  
 then in each such event the Company will provide or
cause to be provided to the Holder a written notice thereof. Such notice shall be provided at least fifteen (15) calendar days prior to the date specified in such notice on which any such action is to be taken. 
  
 11. Representations, Warranties and Covenants. This Warrant is issued
and delivered by the Company and accepted by each Holder on the basis of the following representations, warranties and covenants made by the Company: 
  
 (a) The Company has all necessary authority to issue, execute and deliver this Warrant and to perform its obligations hereunder. This Warrant has
been duly authorized issued, executed and delivered by the Company and is the valid and binding obligation of the Company, enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization or
other similar laws of general application affecting the enforcement of the Holder’s rights or by general equity principals or public policy concerns. 
  
 (b) The shares of Common Stock issuable upon the exercise of this Warrant have been duly authorized and reserved for issuance by the Company and,
when issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable. 
  
 12. Amendment and Waiver. The terms of this Warrant may be amended, modified or waived only with the written consent of the party against which
enforcement of the same is sought. 
  

 7. 

 13. Representations and Covenants of the Holder. This Common Stock Purchase Warrant has been
entered into by the Company in reliance upon the following representations and covenants of the Holder, which by its execution hereof the Holder hereby confirms: 
  
 (a) The Holder is an “accredited investor” as defined in Regulation D under the Securities Act of 1933, as
amended (the “Securities Act”), and the Holder is knowledgeable, sophisticated and experienced in making, and is qualified to make decisions with respect to, investments in shares presenting an investment decision like that involved
in the purchase of the Shares and the Warrant, including investments in securities issued by the Company and investments in comparable companies, and has requested, received, reviewed and considered all information it deemed relevant in making an
informed decision to purchase the Warrant; 
  
 (b) The
Holder is acquiring the Warrant in the ordinary course of its business and for its own account for investment only and with no present intention of distributing the Warrant or any of the Shares or any arrangement or understanding with any other
persons regarding the distribution of the Warrant or the Shares; and 
  
 (c) The Holder will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) the Warrant or any of the Shares except in
compliance with the Securities Act, applicable state securities laws and the respective rules and regulations promulgated thereunder. 
  
 14. Notices, Transfers, Etc. 
  
 (a) Any notice or written communication required or permitted to be given to the Holder may be given by certified mall or delivered to the Holder
at the address most recently provided by the Holder to the Company. 
  
 (b) Subject to compliance with applicable federal and state securities laws, this Warrant may be transferred by the Holder with respect to any or all of the shares purchasable hereunder. Upon surrender of this Warrant to the Company,
together with the assignment notice annexed hereto duly executed, for transfer of this Warrant as an entirety by the Holder, the Company shall issue a new warrant of the same denomination to the assignee. Upon surrender of this Warrant to the
Company, together with the assignment hereof properly endorsed, by the Holder for transfer with respect to a portion of the shares of Common Stock purchasable hereunder, the Company shall issue a new warrant to the assignee, in such denomination as
shall be requested by the Holder hereof, and shall issue to such Holder a new warrant covering the number of shares in respect of which this Warrant shall not have been transferred. 
  
 (c) In case this Warrant shall be mutilated, lost, stolen or destroyed, the Company shall issue a new warrant of like
tenor and denomination and deliver the same (i) in exchange and substitution for and upon surrender and cancellation of any mutilated Warrant or (ii) in lieu of any Warrant lost, stolen or destroyed, upon receipt of an affidavit of the Holder or
other evidence reasonably satisfactory to the Company of the loss, theft or destruction of such Warrant and an indemnification of loss by the Holder in favor of the Company. 
  

 8. 

 15. Transfer to Comply with the Securities Act of 1933. This Warrant may not be exercised and
neither this Warrant nor any of the Shares, nor any interest in either, may be offered, sold, assigned, pledged, hypothecated, encumbered or in any other manner transferred or disposed of, in whole or in part, except in compliance with applicable
United States federal and state securities laws and the terms and conditions hereof. Each Warrant shall bear a legend in substantially the same form as the legend set forth on the first page of this Warrant. Each certificate for Shares issued upon
exercise of this Warrant, unless at the time of exercise such Shares are acquired pursuant to a registration statement that has been declared effective under the Securities Act and applicable blue sky laws, shall bear a legend substantially in the
following form: 
  

	“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”).
SUCH SHARES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF REGISTRATION OR AN EXEMPTION THEREFROM. HEALTHETECH, INC. MAY REQUIRE AN OPINION OF COUNSEL REASONABLY ACCEPTABLE TO IT THAT A PROPOSED TRANSFER OR SALE IS IN COMPLIANCE WITH THE
ACT.”

  
 Any certificate for
any Shares issued at any time in exchange or substitution for any certificate for any Shares bearing such legend (except a new certificate for any Shares issued after the acquisition of such Shares pursuant to a registration statement that has been
declared effective under the Securities Act) shall also bear such legend unless, in the opinion of counsel for the Company, the Shares represented thereby need no longer be subject to the restriction contained herein. The provisions of this Section
15 shall be binding upon all subsequent holders of certificates for Shares bearing the above legend and all subsequent holders of this Warrant, if any. 
  

16. Rights of Holder. Holder shall not, by virtue hereof, be entitled to any rights of a stockholder of the Company, either at law or equity,
and the rights of Holder are limited to those expressed in this Warrant. Nothing contained in this Warrant shall be construed as conferring upon Holder hereof the right to vote or to consent or to receive notice as a stockholder of the Company on
any matters or with respect to any rights whatsoever as a stockholder of the Company. No dividends or interest shall be payable or accrued in respect of this Warrant or the interest represented hereby or the Shares purchasable hereunder until, and
only to the extent that, this Warrant shall have been exercised in accordance with its terms. 
  
 17. No Impairment. Except and to the extent as waived or consented to by the Holder, the Company will not, by amendment of its Amended and Restated Certificate of Incorporation or through any reclassification,
capital reorganization, consolidation, merger, sale or conveyance of assets, dissolution, liquidation, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance of performance of any of the terms of this
Warrant, 

  

 9. 

 
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in
order to protect the rights of the Holder. 
  
 18. Governing
Law. The provisions and terms of this Warrant shall be governed by and construed in accordance with the internal laws of the State of Colorado. 
  
 19. Successors and Assigns. This Warrant shall be binding upon the Company’s successors and assigns and shall inure to the benefit of
the Holder’s successors, legal representatives and permitted assigns. 
  
 20. Business Days. If the last or appointed day for the taking of any action required or the expiration of any rights granted herein shall be a Saturday or Sunday or a legal holiday in California, then
such action may be taken or right may be exercised on the next succeeding day which is not a Saturday or Sunday or such a legal holiday. 
  

 10. 

 IN WITNESS WHEREOF, the Company has duly caused this
Warrant to be signed by its duly authorized officer and to be dated as of the date first written above. 
  

	 Company:

	
	 HEALTHETECH, INC.

		
	 By:
	 	  

	 Name
	 	  

	 Title:
	 	  

  
  

 11. 

 NOTICE OF EXERCISE 
  

	(1)	The undersigned hereby: 

  

	 	[        ]	elects to purchase              shares of Common Stock of the Company pursuant to the terms of the attached
Warrant, and tenders herewith payment of the purchase price of such shares in full, together with all applicable transfer taxes, if any. 

  

	 	[        ]	elects to exercise its net issuance rights pursuant to Section 4 of the attached Warrant with respect to
             shares of Common Stock, and shall tender payment of all applicable transfer taxes, if any. 

  

	(2)	Please issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is specified below:

  

	  

	(Name)
	
	  

	
	  

	
	  

	(Address)

  

	(3)	The undersigned represents that the aforesaid shares are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with,
the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares, all except as in compliance with applicable securities laws. 

  

	
	    	

	(Date)	    	(Signature)
			
	 	  	 	    	

	 	  	 	    	(Print name)

 ASSIGNMENT 
  
 For value received
                                        
                                        
                                        
                             hereby sells,
assigns and transfers unto______________________________________________________________________________________________ 
  

	_________________________________________________________________________________________________________ 

 [Please print or type the name and address of Assignee] 
  
 _________________________________________________________________________________________________________ 
  
 the within Warrant, and does hereby irrevocably constitute and appoint
                                        
     its attorney to transfer the within Warrant on the books of the within named Company with full power of substitution on the premises. 
  

	DATED: ____________________________________	 	 	 	                                      
                                        
                                        
 
			
	 IN THE PRESENCE OF: _________________________
	 	 	 	 
			
	 	 	 	 	 

  

 13.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]